RecruitingNot applicableNCT06507683

Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
First Affiliated Hospital of Chongqing Medical University
Principal Investigator
Jun Zhang
First Affiliated Hospital of Chongqing Medical University
Intervention
simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib(radiation)
Enrollment
32 target
Eligibility
18-75 years · All sexes
Timeline
20242027

Study locations (1)

Collaborators

Peking University Cancer Hospital & Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06507683 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials